Crossmark

B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors

Crossref DOI link: https://doi.org/10.1186/s40425-019-0613-1

Published Online: 2019-06-14

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Damsky, William

Jilaveanu, Lucia

Turner, Noel

Perry, Curtis

Zito, Christopher

Tomayko, Mary

Leventhal, Jonathan

Herold, Kevan

Meffre, Eric

Bosenberg, Marcus

Kluger, Harriet M.
Funding

Funding for this research was provided by:

National Institutes of Health (R01 CA158167, R01 CA227473, P50 CA121974, R01 CA196660, CA204002)

Foundation for the National Institutes of Health (K24 CA172123)

Dermatology Foundation
License Information

Text and Data Mining valid from 2019-06-14
More Information

Article History

Received: 25 January 2019

Accepted: 7 May 2019

First Online: 14 June 2019

Ethics approval and consent to participate

: Patient specimens were de-identified. Animal experiments were approved by Yale IACUC.

: Not applicable.

: MB and WD have served as consultants for Eli Lilly and Company. WD has research funding from Pfizer. HK has received consulting fees from Roche-Genentech, Immunocore, Merck, Alexion, Celldex, Pfizer, Corvus, Biodesix and Nektar, and research funds to her institution from Merck, Bristol Myers Squibb and Apexigen, all outside of the submitted work.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.